Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 3/20 | 0.37 |
| ▸ | MPO | P05164 | 2/20 | 0.36 |
| ▸ | FOS | P01100 | 2/20 | 0.35 |
| ▸ | JUN | P05412 | 2/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | CSF3R | Q99062 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.32 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206433 | 0.92 | F13A1 (0.37) | F13A1MPOFOSJUNLTB4R | |
| SCHEMBL26206385 | 0.90 | FOS (0.36) | F13A1MPOFOSJUNLTB4R | |
| SCHEMBL26206174 | 0.90 | MPO (0.35) | MPOSLC6A4 | |
| SCHEMBL26206394 | 0.90 | F13A1 (0.36) | F13A1MPOFOSJUNLTB4R | |
| SCHEMBL26206383 | 0.87 | FOS (0.36) | MPOFOSJUNFFAR1FFAR4 | |
| SCHEMBL26206467 | 0.85 | LTB4R (0.46) | FOSJUNLTB4RLTB4R2CYSLTR2 | |
| SCHEMBL26206421 | 0.84 | LTB4R (0.44) | MPOFOSJUNLTB4RLTB4R2 | |
| SCHEMBL26206173 | 0.82 | HDAC8 (0.34) | MPO | |
| SCHEMBL26206484 | 0.82 | FFAR4 (0.37) | LTB4RFFAR4CSF3R | |
| SCHEMBL26206133 | 0.81 | MPO (0.33) | MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | F13A1 4060/4885MPO 2309/4885FOS 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.